Efficacy of L-Ornithine L-Aspartate in Recovery of Patients Suffering from Acute Viral Hepatitis
نویسندگان
چکیده
Objective: To assess the efficacy of L-Ornithine L-Aspartate (LOLA) compared with non-LOLA Group in recovery patients acute viral hepatitis.
 Study Design: Quasi-experimental study.
 Place and Duration Study: Department General Medicine, Railway Hospital, Rawalpindi Pakistan, from Aug 2020 to Jan 2021.
 Methodology: All either gender, aged >18 years hepatitis were included. divided into two groups. LOLA-Group (Group-A) was given as an infusion over 24 hours at a dosage 300 grams for three consecutive days. Whereas Group-B had whom not administered. The defined no signs symptoms comparison baseline (clinical improvement), LFTs improved more than half baseline, INR <1.2 seven days’ follow-up.
 Results: Of 128 patients, median age 28 (20-32). A significant difference total bilirubin on seventh day (p-value 0.044) observed (LOLA)-Group. In addition, found be significantly higher among Control Treatment Group, i.e., 54(84.4%) 40(62.5%), respectively 0.005).
 Conclusion: This study showed that outcome is very effective managing hepatitis.
منابع مشابه
L-ornithine-L-aspartate infusion efficacy in hepatic encephalopathy.
OBJECTIVE To determine the efficacy of L-ornithine-L-aspartate in treatment of hepatic encephalopathy. STUDY DESIGN Randomized, placebo-controlled trial. PLACE AND DURATION OF STUDY Department of Gastroenterology and Hepatology, Sheikh Zayed Hospital, Lahore, from February to August 2005. METHODOLOGY Cirrhotic patients with hyperammonemia and overt hepatic encephalopathy were enrolled. Ei...
متن کاملEfficacy of L-ornithine-L-aspartate as an adjuvant therapy in cirrhotic patients with hepatic encephalopathy.
OBJECTIVE To evaluate the efficacy of L-ornithine-L-aspartate (LOLA) as an adjuvant therapy in cirrhotic patients with hepatic encephalopathy (HE). STUDY DESIGN Randomized placebo controlled study. PLACE AND DURATION OF STUDY The Aga Khan University Hospital, Karachi in the year 2003-2004. METHODOLOGY Patients with HE were randomized to receive LOLA or placebo medicine as an adjuvant to t...
متن کاملEfficacy of oral L-ornithine L-aspartate in cirrhotic patients with hyperammonemic hepatic encephalopathy.
Hyperammonemia and associated cerebral edema cause neurological abnormalities in liver disease patients. Although only 15% of ammonia production originates in the colon, management strategies for hepatic encephalopathy (HE) have focused on reducing ammonia generation from the bowel rather than on manipulating systemic mechanisms involved in ammonia metabolism. Administration of L-ornithine L-as...
متن کاملEfficacy of oral L-ornithine L-aspartate in cirrhotic patients with hyperammonemic hepatic encephalopathy
Although the association between neurological abnormalities and liver disease was recognized by Hippocrates in the 5th century B.C., the pathophysiological mechanism responsible for these abnormalities remained obscure until the late 19th century. Liver dysfunction limits the metabolism of substances that are neurotoxic at high concentrations. The neurological manifestations of liver disease ra...
متن کاملPharmacological Study on L-ornithine L-aspartate.
塩屋 明利 ・倉石 弘一 ・柿本 守夫 ・玉真 洋子 In a healthy subject, ammonia produced in the body is excreted by the kidney in the form of urea, the product of the urea cycle (1), or converted into substances useful for the body. In cases of hepatic disorders, on the other hand, blood ammonia level is known to increase (2-6). It is likely that ammonia in high concentrations interferes with the TCA cycle (7) and th...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Pakistan Armed Forces Medical Journal
سال: 2023
ISSN: ['2411-8842', '0030-9648']
DOI: https://doi.org/10.51253/pafmj.v73i3.6473